logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line

< Back

Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line

Drugs

Cancer and Palliative Care

August 2021


Sabatolimab in addition to azacitidine is in clinical development for the treatment of higher risk myelodysplastic syndromes (MDS) in adults. Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. MDS are long-term debilitating and life-threatening diseases
Sabatolimab targets an inhibitory receptor that regulates adaptive and innate immune responses. Azacitidine is already approved for MDS and the addition of sabatolimab may provide synergistic efficacy and safety. If licensed, sabatolimab in addition to azacitidine will offer an additional treatment option for patients with untreated higher risk who currently have few well-tolerated effective therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts